You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

198 Results
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Jan 2018
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
Feb 2018
Regimen
Intent: Palliative
Nov 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Jan 2018
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    erlotinib - Incurable progressive NSCLC, with specific criteria
Oct 2022
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin with Carboplatin - Platinum-Sensitive Recurrent Ovarian Fallopian Tube and Primary Peritoneal Cancer
Jun 2022
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Eribulin - Metastatic or Incurable Locally Advanced - Breast Cancer
Jan 2018

Pages